AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10595814 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IVIg)
Number of subjects: 241
Study 9138980 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyltransferase (NAT) and catalase activity in complicated pregnancies
Number of subjects: 141
Study 9138980 — intervention group
Group type: COMPARATOR
Intervention: N-acetyltransferase (NAT) and catalase activity in physiological pregnancies (control group)
Number of subjects: 141
Study 1924655 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger temperature feedback
Number of subjects: 31
Study 1924655 — intervention group
Group type: COMPARATOR
Intervention: Autogenic training
Number of subjects: 31
Study 31432216 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal CO2 removal (ECCO2R)
Number of subjects: 95
Study 29094998 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional oral formula (GS)
Number of subjects: 99
Study 29094998 — intervention group
Group type: COMPARATOR
Intervention: Nutritional oral formula (GS) and Control (GC)
Number of subjects: 99
Study 25946948 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA 5% cream applied to the cervix
Number of subjects: 92
Study 25946948 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied to the cervix
Number of subjects: 92
Study 23627684 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention (three participatory workshops and organization-wide educational activities)
Number of subjects: 16
Study 23627684 — intervention group
Group type: COMPARATOR
Intervention: Standard care (print resources)
Number of subjects: 16
Study 21906521 — intervention group
Group type: EXPERIMENTAL
Intervention: Tian Gui Capsule
Number of subjects: 47
Study 21906521 — intervention group
Group type: COMPARATOR
Intervention: metformin
Number of subjects: 47
Study 21906521 — intervention group
Group type: COMPARATOR
Intervention: Diane‐35
Number of subjects: 47
Study 18710712 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human leukemia inhibitory factor, 150 microg SC twice daily for 7 days
Number of subjects: 149
Study 18710712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 17584010 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-mg sildenafil
Number of subjects: 16
Study 17584010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15209835 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 330
Study 15209835 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 330
Study 15209835 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 330
Study 11275293 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin administration at 0700 h
Number of subjects: 9
Study 11275293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 11275293 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin administration
Number of subjects: 9
Study 9533119 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile flow during CPB
Number of subjects: 20
Study 9533119 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile flow during CPB
Number of subjects: 20
Study 7915672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous saline and a breathing mixture of even parts of oxygen and nitrous oxide (Entonox)
Number of subjects: 50
Study 7915672 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketobemidone hydrochloride 2.5 mg, midazolam 2.5 mg, and breathing air from a face mask with a demand valve (KHM)
Number of subjects: 50
Study 7915672 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 7915672 — intervention group
Group type: EXPERIMENTAL
Intervention: Entonox
Number of subjects: 50
Study 2610800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cantharis
Number of subjects: 34
Study 2610800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 1103206 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 20
Study 1103206 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 20
Study 31879235 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment plus standard of care (SOC)
Number of subjects: 131
Study 31879235 — intervention group
Group type: COMPARATOR
Intervention: Sham treatments plus SOC
Number of subjects: 131
Study 31142310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cage positioning (posteriorly located cages)
Number of subjects: 953
Study 31142310 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 patients without PCM)
Number of subjects: 953
Study 29233087 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation manual
Number of subjects: 15
Study 29233087 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual plus pedometer
Number of subjects: 15
Study 29233087 — intervention group
Group type: COMPARATOR
Intervention: Standard/usual care
Number of subjects: 15
Study 26693193 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Graded Activity (BGA)
Number of subjects: 62
Study 26693193 — intervention group
Group type: COMPARATOR
Intervention: Conventional Exercise Therapy (CET)
Number of subjects: 62
Study 23311458 — intervention group
Group type: EXPERIMENTAL
Intervention: Employee wellness programme based on cognitive behaviour therapy (CBT) and weekly supervised exercise classes over six weeks.
Number of subjects: 80
Study 23311458 — intervention group
Group type: COMPARATOR
Intervention: Once‐off health promotion talk and educational pamphlets (control group).
Number of subjects: 80
Study 23311458 — intervention group
Group type: EXPERIMENTAL
Intervention: Employee wellness programme (experimental group).
Number of subjects: 80
Study 23311458 — intervention group
Group type: COMPARATOR
Intervention: Control group (once‐off health promotion talk).
Number of subjects: 80
Study 21676046 — intervention group
Group type: EXPERIMENTAL
Intervention: Örebro prevention programme (ÖPP)
Number of subjects: 1752
Study 21676046 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 1752
Study 18772058 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 7513
Study 18772058 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 7513
Study 16139813 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (mean dose 8.7 +/- 7.1 mg/day)
Number of subjects: 24
Study 16139813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12975627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic treatment protocol consisting of 4 different subprotocols
Number of subjects: 0
Study 11076409 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmo-adalat 30 mg once daily for 3 weeks
Number of subjects: 60
Study 11076409 — intervention group
Group type: COMPARATOR
Intervention: Cordipin 10 mg three times a day
Number of subjects: 60
Study 8826515 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure applied to highly tender muscle
Number of subjects: 80
Study 8826515 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure applied to normal muscle
Number of subjects: 80
Study 8826515 — intervention group
Group type: COMPARATOR
Intervention: Pericranial myofascial tenderness evaluation
Number of subjects: 80
Study 1526880 — intervention group
Group type: EXPERIMENTAL
Intervention: Groin dissection
Number of subjects: 58
Study 1526880 — intervention group
Group type: COMPARATOR
Intervention: Groin radiation
Number of subjects: 58
Study 3890049 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 60
Study 3890049 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 60
Study 31036088 — intervention group
Group type: EXPERIMENTAL
Intervention: SIB radiotherapy (95%PTV/PGTV 50.4Gy/59.92Gy/28f)
Number of subjects: 300
Study 31036088 — intervention group
Group type: EXPERIMENTAL
Intervention: SIB radiotherapy concurrent and consolidated with S-1
Number of subjects: 300
Study 28840525 — intervention group
Group type: EXPERIMENTAL
Intervention: SR-LRYGB
Number of subjects: 114
Study 28840525 — intervention group
Group type: COMPARATOR
Intervention: LSG
Number of subjects: 114
Study 28840525 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 114
Study 27179999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecopipam (single large dose)
Number of subjects: 10
Study 27179999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecopipam (open-label extension phase)
Number of subjects: 10
Study 27179999 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10
Study 25033900 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 G vitrectomy
Number of subjects: 40
Study 25033900 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 G vitrectomy
Number of subjects: 40
Study 25033900 — intervention group
Group type: COMPARATOR
Intervention: Diabetic subgroup (20 G)
Number of subjects: 40
Study 25033900 — intervention group
Group type: COMPARATOR
Intervention: Diabetic subgroup (23 G)
Number of subjects: 40
Study 25033900 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic subgroup (20 G)
Number of subjects: 40
Study 25033900 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic subgroup (23 G)
Number of subjects: 40
Study 22686944 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivoglitazone 1.5 mg/day
Number of subjects: 1912
Study 22686944 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivoglitazone 1.0 mg/day
Number of subjects: 1912
Study 22686944 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivoglitazone (both doses)
Number of subjects: 1912
Study 22686944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1912
Study 20202097 — intervention group
Group type: EXPERIMENTAL
Intervention: Microhybrid ('Point 4'; Kerr, Orange, CA, USA)
Number of subjects: 35
Study 20202097 — intervention group
Group type: EXPERIMENTAL
Intervention: Packable ('Packable Premise'; Kerr, Orange, CA, USA)
Number of subjects: 35
Study 20202097 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanofilled ('Nanofilled Premise'; Kerr, Orange, CA, USA)
Number of subjects: 35
Study 20202097 — intervention group
Group type: EXPERIMENTAL
Intervention: All types of restorations
Number of subjects: 35
Study 20202097 — intervention group
Group type: EXPERIMENTAL
Intervention: Packable ('Packable Premise')
Number of subjects: 35
Study 20202097 — intervention group
Group type: EXPERIMENTAL
Intervention: Microhybrid ('Point 4') and Nanofilled ('Nanofilled Premise')
Number of subjects: 35
Study 18931238 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1200 mg preoperatively)
Number of subjects: 50
Study 18931238 — intervention group
Group type: COMPARATOR
Intervention: Placebo (preoperatively)
Number of subjects: 50
Study 16296434 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement containing 1% metronidazole, 1% ciprofloxacin, and 1% cefaclor
Number of subjects: 40
Study 16296434 — intervention group
Group type: COMPARATOR
Intervention: Conventional glass-ionomer cement
Number of subjects: 40
Study 11956510 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg L‐796568
Number of subjects: 12
Study 11956510 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg L‐796568
Number of subjects: 12
Study 11956510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9477752 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen I: follow-up every three months for the first two years, every sixth month in the third year and thereafter once a year.
Number of subjects: 97
Study 9477752 — intervention group
Group type: COMPARATOR
Intervention: Regimen II: follow-up every sixth month the first year, and once a year thereafter.
Number of subjects: 97
Study 9477752 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (I and II)
Number of subjects: 97
Study 7618647 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion at a dose of 0.7 pmol/kg/min for 3 hours
Number of subjects: 27
Study 7618647 — intervention group
Group type: COMPARATOR
Intervention: Vehicle infusion
Number of subjects: 27
Study 2245458 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 62
Study 2245458 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 62
Study 2245458 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy Women)
Number of subjects: 62
Study 385095 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cephradine (1 g applied to the wound at closure)
Number of subjects: 248
Study 385095 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic cephradine (1 g intravenously at induction and 500 mg 4 h later)
Number of subjects: 248
Study 385095 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (control group)
Number of subjects: 248
Study 30214066 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 197
Study 30214066 — intervention group
Group type: COMPARATOR
Intervention: Genetic Counselor (GC) only
Number of subjects: 197
Study 29546579 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2
Study 29546579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 29546579 — intervention group
Group type: COMPARATOR
Intervention: Insulin or Dapagliflozin
Number of subjects: 2
Study 29546579 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (in vitro)
Number of subjects: 2
Study 26817957 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥ 60 years
Number of subjects: 854
Study 26817957 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous provoked VTE
Number of subjects: 854
Study 26817957 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoker status
Number of subjects: 854
Study 26817957 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cancer detection
Number of subjects: 854
Study 25349316 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed feedback sessions (18-item evaluation form)
Number of subjects: 476
Study 25349316 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple feedback sessions (single-item evaluation form)
Number of subjects: 476
Study 25349316 — intervention group
Group type: COMPARATOR
Intervention: No formal presentation feedback (control)
Number of subjects: 476
Study 23201768 — intervention group
Group type: EXPERIMENTAL
Intervention: 15.0 g egg white protein; 75 kcal
Number of subjects: 30
Study 23201768 — intervention group
Group type: COMPARATOR
Intervention: 17.5 g maltodextrin, 78 kcal
Number of subjects: 30
Study 19960001 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate (three capsules per day, ingested 30 min before the main meal)
Number of subjects: 48
Study 19960001 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo, three capsules per day, ingested 30 min before the main meal)
Number of subjects: 48
Study 17408408 — intervention group
Group type: EXPERIMENTAL
Intervention: LY517717 100 mg
Number of subjects: 507
Study 17408408 — intervention group
Group type: EXPERIMENTAL
Intervention: LY517717 125 mg
Number of subjects: 507
Study 17408408 — intervention group
Group type: EXPERIMENTAL
Intervention: LY517717 150 mg
Number of subjects: 507
Study 17408408 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg
Number of subjects: 507
Study 17408408 — intervention group
Group type: EXPERIMENTAL
Intervention: LY517717 (all doses)
Number of subjects: 507
Study 17408408 — intervention group
Group type: EXPERIMENTAL
Intervention: LY517717 and Enoxaparin
Number of subjects: 507
Study 16268983 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without left ventricular hypertrophy
Number of subjects: 83
Study 16268983 — intervention group
Group type: COMPARATOR
Intervention: Patients with left ventricular hypertrophy
Number of subjects: 83
Study 12223253 — intervention group
Group type: EXPERIMENTAL
Intervention: CX516 (300 mg tid to 900 mg tid over 4 weeks)
Number of subjects: 4
Study 12223253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 10403587 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein/carbohydrate diet (29% protein, 61% carbohydrate, 10% fat)
Number of subjects: 8
Study 10403587 — intervention group
Group type: COMPARATOR
Intervention: High fat diet (9% protein, 30% carbohydrate, 61% fat)
Number of subjects: 8
Study 8744964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact pairs presented simultaneously at study and test
Number of subjects: 0
Study 8744964 — intervention group
Group type: COMPARATOR
Intervention: Recombined pairs presented simultaneously at study and test
Number of subjects: 0
Study 8744964 — intervention group
Group type: COMPARATOR
Intervention: Sequential presentation at test
Number of subjects: 0
Study 8744964 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit speeded-recognition task
Number of subjects: 0
Study 2035279 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine
Number of subjects: 139
Study 2035279 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg fluoxetine
Number of subjects: 139
Study 2035279 — intervention group
Group type: COMPARATOR
Intervention: 50 mg clomipramine
Number of subjects: 139
Study 7071301 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory feedback stimulus group
Number of subjects: 40
Study 7071301 — intervention group
Group type: COMPARATOR
Intervention: Stimulus control group
Number of subjects: 40
Study 30836995 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal drawn carts as the most common mode of transport to primary health facilities
Number of subjects: 1479
Study 30836995 — intervention group
Group type: EXPERIMENTAL
Intervention: Median travel time to health facilities
Number of subjects: 1479
Study 30836995 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial resources for transport
Number of subjects: 1479
Study 30836995 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportation barriers to healthcare access
Number of subjects: 1479
Study 28697780 — intervention group
Group type: EXPERIMENTAL
Intervention: Sciatic nerve block (SNB)
Number of subjects: 78
Study 28697780 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration of analgesia with steroid (LIA)
Number of subjects: 78
Study 28697780 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 78
Study 26032118 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block (ropivacaine 0.5%, 20 ml on each side)
Number of subjects: 70
Study 26032118 — intervention group
Group type: COMPARATOR
Intervention: Sham block (isotonic saline 0.9%, 20 ml on each side)
Number of subjects: 70
Study 23859428 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 5238
Study 23859428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5238
Study 22381601 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 12-hour dosing interval
Number of subjects: 228
Study 22381601 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone 24-hour dosing interval
Number of subjects: 228
Study 20026554 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counselling by a dietician (D)
Number of subjects: 134
Study 20026554 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional plus exercise counselling by a dietician and physiotherapist (D + E)
Number of subjects: 134
Study 20026554 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 134
Study 16675095 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IMN)
Number of subjects: 0
Study 16675095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16222900 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg and Ramipril 10 mg
Number of subjects: 300
Study 16222900 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan 80 mg
Number of subjects: 300
Study 16222900 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI assessment of left ventricular structure and function
Number of subjects: 300
Study 16222900 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP changes during follow-up
Number of subjects: 300
Study 12171833 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually adjustable intraoral sleep apnea device (ISAD)
Number of subjects: 20
Study 12171833 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 20
Study 10102306 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg positioning
Number of subjects: 19
Study 10102306 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 19
Study 8565983 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (once daily for three days)
Number of subjects: 484
Study 8565983 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid (thrice daily for ten days)
Number of subjects: 484
Study 8565983 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 484
Study 8565983 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid
Number of subjects: 484
Study 2178656 — intervention group
Group type: EXPERIMENTAL
Intervention: Single heparin bolus of 10,000 units (protocol I)
Number of subjects: 40
Study 2178656 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin bolus of 10,000 units plus continuous infusion of 2000 units/hour (protocol II)
Number of subjects: 40
Study 2178656 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin infusion at the rate of 2000 units/hour for 24 hours post-angioplasty
Number of subjects: 40
Study 2178656 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated clotting time of arterial blood
Number of subjects: 40
Study 7451515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ender's pins
Number of subjects: 100
Study 7451515 — intervention group
Group type: COMPARATOR
Intervention: Compression sliding hip screw
Number of subjects: 100
Study 31751333 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 40 mg/kg
Number of subjects: 81
Study 27658651 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel dispatch protocol
Number of subjects: 125
Study 27658651 — intervention group
Group type: COMPARATOR
Intervention: Standard dispatch protocol
Number of subjects: 125
Study 25942482 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (PN)
Number of subjects: 4640